Agios Pharmaceuticals (AGIO) EBT (2012 - 2026)

Agios Pharmaceuticals has reported EBT for 15 years, with the latest figure at -$99.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 9.6% year-over-year to -$99.2 million; the trailing twelve-month figure through Mar 2026 stood at -$424.3 million (down 159.97% YoY), and the FY2025 full-year result was -$413.8 million, down 157.63% from the prior year.
• EBT for Q1 2026 stood at -$99.2 million, up from -$109.1 million in the prior quarter.
• The five-year high for EBT was $1.0 billion in Q3 2024, with the low at -$112.5 million in Q2 2025.
• Historically, EBT has averaged -$31.3 million across 5 years, with a median of -$95.8 million in 2022.
• Annual changes were most pronounced in 2024 — EBT surged 1196.14% — and 2025, when it plunged 110.33%.
• Agios Pharmaceuticals' EBT stood at -$92.7 million in 2022, then retreated by 3.51% to -$95.9 million in 2023, then slipped by 9.86% to -$105.4 million in 2024, then fell by 3.47% to -$109.1 million in 2025, then advanced by 9.01% to -$99.2 million in 2026.
• The last three EBT figures came in at -$99.2 million (Q1 2026), -$109.1 million (Q4 2025), and -$103.4 million (Q3 2025), per Business Quant data.